Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (15)	9/3/2002 12:28:25 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GNLB Had a good UP-MOVE Friday after it announced that it had received an approval letter from the FDA for Prestara, albeit the approval is contingent upon the successful completion of an additional clinical trial confirming the positive effect of the drug on bone mineral density in women with mild to moderate systemic lupus erythematosus while on low-dose glucocorticoids. The stock was up 102.88% on volume of 15.638 millions (about 32.6x its daily average) In the mean time WPI,which holds an exclusive license for Prestara in North America, was up only 1% on less than its average volume . siliconinvestor.com siliconinvestor.com siliconinvestor.com siliconinvestor.com Bernard